AIMS: Invasive breast carcinoma (IBC) with neuroendocrine (NE) differentiation has been controversial in terms of its definition and clinical outcome. We investigated the incidence and clinical significance of NE differentiation in patients with IBC. METHODS AND RESULTS: We performed immunohistochemistry for NE markers, chromogranin-A and synaptophysin on 1428 IBC samples using tissue microarrays and classified cases with NE differentiation into two groups, focal (1-49% tumour cells positive for any NE marker) and diffuse (≥50% tumour cells positive) groups. Fifty-nine cases (4.1%) showed NE differentiation immunohistochemically, and the majority did not show typical NE morphology. The presence of NE differentiation showed a significant association with positive oestrogen receptor (P = 0.001) and progesterone receptor (P = 0.008) status. Patients with NE differentiation showed worse overall survival (OS) and disease-free survival (DFS) than those without NE differentiation in both univariate (P < 0.001 for both) and multivariate (OS, P = 0.004; DFS, P < 0.001) analyses. CONCLUSIONS: IBC with NE differentiation is a distinct subtype of mammary carcinoma with an aggressive clinical outcome.
AIMS: Invasive breast carcinoma (IBC) with neuroendocrine (NE) differentiation has been controversial in terms of its definition and clinical outcome. We investigated the incidence and clinical significance of NE differentiation in patients with IBC. METHODS AND RESULTS: We performed immunohistochemistry for NE markers, chromogranin-A and synaptophysin on 1428 IBC samples using tissue microarrays and classified cases with NE differentiation into two groups, focal (1-49% tumour cells positive for any NE marker) and diffuse (≥50% tumour cells positive) groups. Fifty-nine cases (4.1%) showed NE differentiation immunohistochemically, and the majority did not show typical NE morphology. The presence of NE differentiation showed a significant association with positive oestrogen receptor (P = 0.001) and progesterone receptor (P = 0.008) status. Patients with NE differentiation showed worse overall survival (OS) and disease-free survival (DFS) than those without NE differentiation in both univariate (P < 0.001 for both) and multivariate (OS, P = 0.004; DFS, P < 0.001) analyses. CONCLUSIONS: IBC with NE differentiation is a distinct subtype of mammary carcinoma with an aggressive clinical outcome.
Authors: Caterina Marchiò; Felipe C Geyer; Charlotte Ky Ng; Salvatore Piscuoglio; Maria R De Filippo; Marco Cupo; Anne M Schultheis; Raymond S Lim; Kathleen A Burke; Elena Guerini-Rocco; Mauro Papotti; Larry Norton; Anna Sapino; Britta Weigelt; Jorge S Reis-Filho Journal: J Pathol Date: 2016-12-26 Impact factor: 7.996
Authors: Billy Shui-Wun Lai; Julia Y Tsang; Ivan K Poon; Yan Shao; Siu-Ki Chan; Fiona K Tam; Sai-Yin Cheung; Ka-Ho Shea; Gary M Tse Journal: Oncologist Date: 2020-06-16
Authors: M Anlauf; M Neumann; S Bomberg; K Luczak; S Heikaus; C Gustmann; C Antke; S Ezziddin; C Fottner; M Pavel; U-F Pape; A Rinke; H Lahner; M Schott; B Cremer; D Hörsch; R P Baum; U Groh; I Alkatout; C Rudlowski; P Scheler; T K Zirbes; J Hoffmann; T Fehm; H E Gabbert; S E Baldus Journal: Pathologe Date: 2015-05 Impact factor: 1.011
Authors: Do Hyung Lee; Ah Young Park; Bo Kyoung Seo; Young Sik Kim; Ki Yeol Lee; Sang Hoon Cha Journal: J Breast Cancer Date: 2015-12-23 Impact factor: 3.588
Authors: Marion Lavigne; Emmanuelle Menet; Jean-Christophe Tille; Marick Lae; Laetitia Fuhrmann; Claire Bonneau; Gabrielle Deniziaut; Samia Melaabi; Charlotte C K Ng; Caterina Marchiò; Roman Rouzier; Ivan Bièche; Anne Vincent-Salomon Journal: Mod Pathol Date: 2017-09-08 Impact factor: 7.842